

Market Pricing Guide for Approved Cell Therapies Worldwide



BioInformant.com

TABLE OF CONTENTS

1.	THE PRICING OF GLOBALLY APPROVED CELL THERAPIES	7
1.1	Overview of Globally Approved Cell Therapies	7
1.2	Product Approval Counts for Globally Approved Cell Therapies	8
2.	PRICING CATEGORIES FOR CELL THERAPY PRODUCTS	10
2.1	Average Price Range for Cell Therapy Products, by Category	10
2.2	Full Price Range for Cell Therapy Products, by Category (Including Low and High Outliers).....	12
3.	PREDICTIVE VARIABLES FOR CELL THERAPY PRICING	13
4.	PRICING OF APPROVED CELL THERAPY PRODUCTS	14
4.1	Pricing of Globally Approved Cell-Based Wound Care Products	14
4.1.1	Grafix core	15
4.1.2	ActiGraft.....	15
4.1.3	Apligraf.....	15
4.1.4	EpiFix.....	16
4.1.5	Dermagraft.....	16
4.1.6	AmnioExcel.....	16
4.1.7	NEOX 1K	16
4.1.8	OrCel	17
4.1.9	TheraSkin	17
4.1.10	Kaloderm	17
4.1.11	KeraHeal.....	17
4.1.12	Affinity	18
4.1.13	AlloPatch.....	18
4.1.14	AmnioBand	18
4.1.15	AlloDerm	18
4.1.16	StrataGraft	19
4.1.17	Hyalograft 3D	19
4.1.18	Epicel.....	19
4.1.19	JACE.....	19
4.1.20	TransCyte	20
4.1.21	NuCel.....	20
4.2	Pricing of Globally Approved Cell-Based Cartilage and Bone Matrix Products	21
4.2.1	Chondron (Autologous Cartilage Replacement)	22
4.2.2	CartiLife	22
4.2.3	MACI.....	22
4.2.4	JACC	23
4.2.5	CartiHeal Agili-C	23
4.2.6	Spherox	23
4.2.7	Novocart 3D.....	23
4.2.8	Ortho-ACI.....	24
4.2.9	Ossron	24
4.2.10	Cartigrow	24
4.2.11	Ossgrow.....	24
4.2.12	DeNovo NT	25
4.2.13	Carticel.....	25
4.2.14	Trinity Evolution	25
4.2.15	BIO4.....	25
4.2.16	Trinity ELITE	26
4.2.17	Cellentra VCBM.....	26

4.2.18	Osteocel.....	26
4.2.19	ViviGen	26
4.2.20	VIA Graft.....	27
4.2.21	PrimaGen.....	27
4.2.22	V92	27
4.2.23	SCYLLA.....	28
4.2.24	Magnus	28
4.2.25	CeLLogix.....	28
4.2.26	InFUSE	28
4.2.27	Gem 21S.....	29
4.2.28	Augment	29
4.2.29	OsteoAMP	29
4.3	Pricing of Globally Approved Intravenous Cell Therapies.....	31
4.3.1	Amtagvi (lifileucel)	31
4.3.2	APCeden	31
4.3.3	CreaVax RCC.....	32
4.3.4	Ebvallo (tabelecleucel)	32
4.3.5	Immuncell LC.....	32
4.3.6	Provenge (sipuleucel-T)	33
4.3.7	Tecelra (afamitrisgene autoleucel)	33
4.3.8	Cartistem	33
4.3.9	Cellgram-AMI.....	34
4.3.10	Cupistem.....	34
4.3.11	Holoclar.....	34
4.3.12	Lantidra (donislecel)	35
4.3.13	LaViv (azficel-T).....	35
4.3.14	Neuronata-r (lenzumestrocel).....	35
4.3.15	Omisirge (omidubicel).....	35
4.3.16	Queencell.....	36
4.3.17	Rosmir	36
4.3.18	Stemirac.....	36
4.3.19	Stempeucel.....	37
4.3.20	TEMCELL	37
4.3.21	Vyznova (neltependocel)	37
4.3.22	Rynocil (remestemcel-L), previously Prochymal	37
4.3.23	MasestroCell.....	38
4.3.24	Ruibosheng (amimestrocel).....	38
4.4	Pricing of Globally Approved Gene-Modified T Cell Therapies (CAR- T Therapies) ...	40
4.4.1	Kymriah (tisagenlecleucel)	40
4.4.2	Yescarta (axicabtagene ciloleucel).....	41
4.4.3	Tecartus (brexucabtagene autoleucel).....	41
4.4.4	Breyanzi (lysocabtagene maraleucel)	42
4.4.5	Abecma (idecabtagene vicleucel)	42
4.4.6	Relma-cel (relmacabtagene autoleucel).....	42
4.4.7	Carvykti (ciltacabtagene autoleucel)	43
4.4.8	Fucaso (equecabtagene autoleucel)	43
4.4.9	NexCAR19 (actalycabtagene autoleucel)	43
4.4.10	Yuanruida (inaticabtagene autoleucel).....	44
4.4.11	Zevor-cel (zevorcabtagene autoleucel)	44
4.4.12	Qartemi (varnimcabtagene autoleucel)	44
4.4.13	Aucatzyl (obecabtagene autoleucel)	44
5.	COMPONENT COSTS ASSOCIATED WITH CAR-T THERAPY	46

6.	REIMBURSEMENT FOR CAR-T THERAPIES	47
6.1	Reimbursement in the U.S. for CAR-T Therapies.....	47
6.2	Reimbursement for CAR-T Therapies in Europe	48
6.2.1	Conditional Coverage for CAR-T Therapies in the E.U.....	49
6.3	Reimbursement for CAR-T Cell Therapies in Asia	49
6.3.1	Reimbursement for CAR-T Cell Therapies in Australia.....	49
6.3.2	Reimbursement for CAR-T Cell Therapies in Singapore	50
6.3.3	Reimbursement for CAR-T Cell Therapies in Japan	51
6.3.4	Reimbursement for CAR-T Cell Therapies in Republic of Korea	51
6.3.5	Reimbursement for CAR-T Cell Therapies in China	51
6.3.6	Reimbursement for CAR-T Therapies in Malaysia.....	51
6.3.7	Reimbursement for CAR-T Therapies in India	52
7.	PRICING OF APPROVED GENE-MODIFIED STEM CELL THERAPIES	53
7.1	Strimvelis.....	53
7.2	Casgevy (exagamglogene autotemcel).....	54
7.3	Lyfgenia (lovotibeglogene autotemcel)	54
8.	EMERGING PAYMENT & FINANCING MODELS FOR CELL THERAPIES	55
8.1	Alternative Payment Models for Cell and Gene Therapies	55
8.2	Conclusions.....	56
9.	REFERENCE GUIDE FOR THE APPROVAL DATES OF CELL THERAPIES	58

INDEX OF TABLES

TABLE 2.1:	Average Price Range for Cell Therapy Products, by Category (USD \$)	11
TABLE 2.2:	Full Price Ranges for Cell Therapy Product Categories (USD \$)	12
TABLE 4.1:	Pricing of Globally Approved Cell-Based Wound Care Products	21
TABLE 4.2:	Pricing of Globally Approved Cell-Based Cartilage & Bone Matrix Products	30
TABLE 4.3:	Pricing of Globally Approved Intravenous Cell Therapy Products	39
TABLE 4.4:	Pricing of Globally Approved Gene Modified T Cell Therapies.....	45
TABLE 5.1:	Component Costs Associated with CAR-T Therapy	46
TABLE 6.1:	EU-Approved CAR-T Cell Therapies	48
TABLE 7.1:	Pricing of Gene-Modified Stem Cell Therapies.....	54
TABLE 9.1:	Regulatory Approval Dates for Cell Therapy Products	58
TABLE 9.1:	(CONTINUED)	59
TABLE 9.1:	(CONTINUED)	60

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the cell therapy industry.

Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, BioInformant has collected 19+ years of historical data, providing a robust and unusual foundation on which to base its market research and make future market forecasts.

Serving market leaders that include Pfizer, Goldman Sachs, GE Healthcare, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.

BioInformant's team of analysts operate one of the world's largest cell therapy industry news sites, BioInformant.com, attracting nearly one million readers per year.

